<DOC>
	<DOCNO>NCT02781805</DOCNO>
	<brief_summary>The goal study mechanistically define potential anticancer activity osteoporosis bisphosphonate ( BP ) drug alendronate , extend analysis learn novel information impact BP gamma delta ( γδ ) T cell breast tissue well epithelial breast cell differentiation high-risk woman . To end , design BP `` window trial '' examine effect 1 - 3 week administration alendronate woman high-risk breast cancer , level immunosurveillance mammary epithelial cell differentiation .</brief_summary>
	<brief_title>Pilot Study Bisphosphonates Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients refer risk reduction mastectomy ( ex . BRCA highrisk gene mutation , strong family history breast cancer , history LCIS , ADH , ALH DCIS undergo bilateral mastectomy prophylactic contralateral mastectomy ) Patients premenopausal define individual least six menstrual cycle past year Patients must 18 year age older The effect Alendronate develop fetus unknown . For reason , heterosexual woman must agree use TWO effective form birth control duration study participation 8 week follow last dose study medication . Women must combine hormonal birth control method ( e.g . combine oral contraceptive pill , vaginal ring , skin patch , injection , copper IUD ) continuous use &gt; 90 day prior study entry ( except case copper IUD ) , nonhormonal birth control method ( e.g . diaphragm , cervical cap , cervical shield spermicide , contraceptive sponge , condom ( male female ) spermicide ) . Women hysterectomy intact functioning ovary , woman Fallopian tubes cut , tie , seal , woman sterilization implant ( e.g . Adiana , Essure ) place &gt; 3 month prior begin study drug consider able bear child therefore eligible participate without use concurrent birth control . Females childbearing potential must negative pregnancy test within current menstrual cycle within 7 day start drug . Patients must recover major infection and/or surgical procedure , opinion investigator , significant active concurrent medical illness preclude protocol treatment Participants must ability understand , willingness sign , write informed consent form Patients previous diagnosis invasive breast cancer Patients postmenopausal ( defined 12 consecutive month without menstrual period ) . Patients implant sample breast Pregnant lactate woman exclude study . Breastfeeding must discontinue duration study participation 8 week last dose study agent Patients English native language Patients current previous bisphosphonate therapy Patients history allergic reaction attribute compound similar chemical biologic composition alendronate bisphosphonates . Patients esophageal dysmotility Patients unable sit stay 30 minute take oral dose Patients take nonsteroidal antiinflammatory drug ( NSAIDs ) past two week Patients receive chemotherapy malignancy past 5 year Patients treat medical condition ( ulcerative colitis ) chronic steroid 2 year prior plan mastectomy surgery Patients calculate creatinine clearance ( CockroftGault ) less 35 mL/min Patients history hypocalcemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>